[go: up one dir, main page]

NO20081250L - Kombinasjon av hypnotisk middel med langtidsvirkning og hypnotisk middel med korttidsvirkning, samt terapeutisk anvendelse av samme - Google Patents

Kombinasjon av hypnotisk middel med langtidsvirkning og hypnotisk middel med korttidsvirkning, samt terapeutisk anvendelse av samme

Info

Publication number
NO20081250L
NO20081250L NO20081250A NO20081250A NO20081250L NO 20081250 L NO20081250 L NO 20081250L NO 20081250 A NO20081250 A NO 20081250A NO 20081250 A NO20081250 A NO 20081250A NO 20081250 L NO20081250 L NO 20081250L
Authority
NO
Norway
Prior art keywords
hypnotic agent
term effect
combination
short
long
Prior art date
Application number
NO20081250A
Other languages
English (en)
Inventor
Alain Cuine
Michel Decobert
Dominique Francon
Henry Saunal
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20081250L publication Critical patent/NO20081250L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse angår kombinasjon av: et korttidsvirkende hypnotisk middel som er valgt fra blant en modulator av reseptorer GABA-A, et benzodiazepin, et fenotiazin, et melatoninderivat og en melatoninreseptoragonist; og et langtidsvirkende hypnotisk middel som er valgt fra blant en modulator av reseptorer GABA-A, et benzodiazepin, en antagonist av reseptorer av 5HT2A og en kalsiumionemodulator, for behandling av søvnforstyrrelser. Oppfinnelsen angår også galeniske formuleringer som inneholder nevnte kombinasjon.
NO20081250A 2005-08-19 2008-03-10 Kombinasjon av hypnotisk middel med langtidsvirkning og hypnotisk middel med korttidsvirkning, samt terapeutisk anvendelse av samme NO20081250L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508643A FR2889811B1 (fr) 2005-08-19 2005-08-19 Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
PCT/FR2006/001830 WO2007020337A1 (fr) 2005-08-19 2006-07-27 Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte et son application therapeutique

Publications (1)

Publication Number Publication Date
NO20081250L true NO20081250L (no) 2008-05-13

Family

ID=36273351

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081250A NO20081250L (no) 2005-08-19 2008-03-10 Kombinasjon av hypnotisk middel med langtidsvirkning og hypnotisk middel med korttidsvirkning, samt terapeutisk anvendelse av samme

Country Status (25)

Country Link
US (2) US20080181943A1 (no)
EP (1) EP1919473B1 (no)
JP (1) JP5215851B2 (no)
KR (1) KR20080039909A (no)
CN (1) CN101267819B (no)
AR (1) AR055123A1 (no)
AU (1) AU2006281334B2 (no)
BR (1) BRPI0614792A2 (no)
CA (1) CA2618212C (no)
CR (1) CR9695A (no)
EA (1) EA014294B1 (no)
EC (1) ECSP088131A (no)
FR (1) FR2889811B1 (no)
HN (1) HN2008000278A (no)
IL (1) IL188823A0 (no)
MA (1) MA29766B1 (no)
MX (1) MX2008002275A (no)
NO (1) NO20081250L (no)
NZ (1) NZ565880A (no)
SG (1) SG165316A1 (no)
TN (1) TNSN08027A1 (no)
TW (1) TW200738238A (no)
UA (1) UA93209C2 (no)
WO (1) WO2007020337A1 (no)
ZA (1) ZA200800968B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
WO2009084023A2 (en) * 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
EP2236511A4 (en) 2007-12-21 2011-04-13 Alla Chem Llc LIGANDS OF ALPHA ADRENOCEPTORS AND OF DOPAMINE, HISTAMIN, IMIDAZOLIN AND SEROTONIN RECEPTORS AND THEIR APPLICATION THEREOF
EP2365805A1 (en) * 2008-11-13 2011-09-21 Sanofi Method of treating sleep disorders using eplivanserin
FR2938534B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Procede de preparation de l'hemifumarate d'eplivanserine
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
CA2752233C (en) 2009-02-13 2017-01-03 Romark Laboratories L.C. Controlled release pharmaceutical formulations of nitazoxanide
EP2255807A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Method of treating sleep disorders using the combination of eplivanserin and zolpidem
EP2255726A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Spectral profile of SWS enhancing drugs
WO2012109695A1 (en) * 2011-02-16 2012-08-23 Casal Y Galzov Ramon Ernesto Drug compositions for the treatment of insomnia
EP2717698A4 (en) 2011-06-09 2015-01-07 Requis Pharmaceuticals Inc ANTI-HISTAMINE IN COMBINATION WITH FOOD SUPPLEMENTS FOR IMPROVED HEALTH
CN102579383A (zh) * 2012-04-09 2012-07-18 南京正科制药有限公司 右佐匹克隆缓释片
NZ720813A (en) * 2014-02-06 2021-12-24 Lan Bo Chen Composition and method for aiding sleep
WO2016209061A1 (ko) 2015-06-26 2016-12-29 한국유나이티드제약 주식회사 모사프리드와 라베프라졸의 복합제제
CN105596313B (zh) * 2016-02-17 2018-06-29 新乡医学院第一附属医院 一种具有反向药理功能的用于治疗失眠的胶囊制剂
CN105997958B (zh) * 2016-07-12 2019-03-26 中国人民解放军白求恩医务士官学校 一种口腔外用制剂及其制备方法
LT3777842T (lt) * 2016-10-31 2025-04-10 Neurim Pharmaceuticals Ltd. Melatonino mini tabletės ir jų gamybos būdas
US11040984B2 (en) * 2016-12-30 2021-06-22 Medshine Discovery Inc. Quinazoline compound for EGFR inhibition
EP3746126B1 (en) 2018-01-30 2024-07-31 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea or simple snoring
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
SG11202108225QA (en) * 2019-02-08 2021-08-30 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
TW202208373A (zh) 2020-05-20 2022-03-01 美商瑟泰戈治療學股份有限公司 環經氘化之加波沙朵及其用於治療精神病症用途
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains
CN115919806A (zh) * 2022-12-22 2023-04-07 南京乐韬生物科技有限公司 一种gaba缓释胶囊的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
CA2332521C (en) * 1998-06-09 2009-02-10 Takeda Chemical Industries, Ltd. Pharmaceutical composition for treating or preventing sleep disorders
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005063297A2 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
JP2009500421A (ja) * 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及び抗うつ薬の組み合わせ
JP2009504760A (ja) * 2005-08-19 2009-02-05 アベンティス・ファーマスーティカルズ・インコーポレイテツド 催眠剤及びＲ（＋）−α−（２，３−ジメトキシ−フェニル）−１−［２−（４−フルオロフェニル）エチル］−４−ピペリジンメタノールの組み合わせ物並びに治療でのその使用
RU2008110498A (ru) * 2005-08-19 2009-09-27 Авентис Фармасьютикалз Инк. (Us) Комбинация снотворного средства и замещенного соединения бис арила и гетероарила и ее терапевтическое применение

Also Published As

Publication number Publication date
US20100291204A1 (en) 2010-11-18
HN2008000278A (es) 2011-03-30
FR2889811A1 (fr) 2007-02-23
EA014294B1 (ru) 2010-10-29
AR055123A1 (es) 2007-08-08
WO2007020337A1 (fr) 2007-02-22
EP1919473B1 (fr) 2012-12-05
CA2618212A1 (fr) 2007-02-22
KR20080039909A (ko) 2008-05-07
CA2618212C (fr) 2014-03-25
MA29766B1 (fr) 2008-09-01
TNSN08027A1 (en) 2009-07-14
BRPI0614792A2 (pt) 2011-04-12
TW200738238A (en) 2007-10-16
NZ565880A (en) 2011-07-29
JP5215851B2 (ja) 2013-06-19
US20080181943A1 (en) 2008-07-31
CN101267819A (zh) 2008-09-17
CR9695A (es) 2008-02-20
ECSP088131A (es) 2008-02-20
UA93209C2 (ru) 2011-01-25
EP1919473A1 (fr) 2008-05-14
MX2008002275A (es) 2008-03-27
FR2889811B1 (fr) 2009-10-09
JP2009504713A (ja) 2009-02-05
ZA200800968B (en) 2009-04-29
SG165316A1 (en) 2010-10-28
CN101267819B (zh) 2012-05-30
AU2006281334A1 (en) 2007-02-22
EA200800618A1 (ru) 2008-06-30
IL188823A0 (en) 2008-12-29
AU2006281334B2 (en) 2012-10-18
HK1124541A1 (en) 2009-07-17

Similar Documents

Publication Publication Date Title
NO20081250L (no) Kombinasjon av hypnotisk middel med langtidsvirkning og hypnotisk middel med korttidsvirkning, samt terapeutisk anvendelse av samme
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
NO20073664L (no) Peptider med neuropeptid-2-reseptor (Y2R) agonist aktivitet
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
ECSP099775A (es) Terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario
UY29246A1 (es) Nuevos compuestos
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
UY27870A1 (es) Nuevos derivados de quinuclidina-amida
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
NO20085099L (no) Puritonderivativer som HM74A agonister
NO20051260L (no) Arylsubstituerte diazabicykloalkaner som nikotinacetylcholinagonister
SV2010003642A (es) Compuestos
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
NO20084435L (no) C-MET proteinkinaseinhibitorer
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
HN2006007884A (es) Derivados de oxiindol
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application